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Abstract
Objective To assess the comparative costs and effects of interventions
to combat five neuropsychiatric conditions (schizophrenia, bipolar
disorder, depression, epilepsy, and heavy alcohol use).
Design Cost effectiveness analysis based on an epidemiological model.
Setting Two epidemiologically defined World Health Organization
sub-regions of the world: countries in sub-Saharan Africa with very high
adult and high child mortality (AfrE); and countries in South East Asia
with high adult and high child mortality (SearD).
Data sources Published studies, costing databases.
Main outcome measures Cost per capita and cost per disability adjusted
life year (DALY) averted, expressed in international dollars ($Int) for the
year 2005.
Results Across 44 assessed intervention strategies for the five
neuropsychiatric conditions, cost effectiveness values differed by as
much as two orders of magnitude (from $Int100–250 to $Int10 000–25
000 for a year of healthy life gained). In both sub-regions, inpatient based
treatment of schizophrenia with newer antipsychotic drugs was the most
costly and least cost effective strategy. The most cost effective strategies
in the African sub-region related to population based alcohol control,
while in the South East Asian sub-region the most cost effective
intervention was drug treatment of epilepsy in primary care. The
cumulative cost per capita of the most cost effective set of interventions
covering all five conditions was estimated at $Int4.90–5.70. This package
comprises interventions for epilepsy (older first line antiepileptic drugs);
depression (generically produced newer antidepressants and
psychosocial treatment); bipolar disorder (mood stabiliser drug lithium);
schizophrenia (neuroleptic antipsychotic drugs and psychosocial
treatment); and heavy alcohol use (increased taxation and its
enforcement, reduced access, and, in the African sub-region, advertising
bans and brief advice to heavy drinkers in primary care).
Conclusions Reallocation of resources to cost effective intervention
strategies would increase health gain, save money and help implement
much needed expansion of services for neuropsychiatric conditions in
low resource settings.
Introduction
Despite accounting for at least a quarter of total
non-communicable disease burden, ill health resulting from
mental, neurological, and substance use disorders remains a
neglected and under-resourced element within healthcare
systems in low and middle income countries.
1 Many countries
currentlyallocatelessthan2%,oreven1%,ofthehealthbudget
to the treatment and prevention of these disorders, with most
funds typically directed towards the running costs of mental
hospital services.
2 The situation is particularly bleak in low
income countries, where on average there is one psychiatrist
per1.7millioninhabitantsandonepsychiatricinpatientbedper
42 000 inhabitants.
2 Unsurprisingly, there is a large treatment
gap for neuropsychiatric conditions in developing regions
3; for
epilepsy, the treatment gap has been put at 56%, while, for
people with severe mental disorders, a large multi-country
survey showed that 76–85% did not receive any treatment in
the previous 12 months.
4
The current state of mental healthcare in resource constrained
countries raises questions not only about the adequacy and
distribution of resources for treating and preventing disorders,
but also about the efficiency with which the resources are used.
By simultaneously examining the cost effectiveness of a core
set of interventions across a range of key neuropsychiatric
conditions, this paper primarily addresses the question of
efficiency.Insodoing,italsoestablisheswhatlevelofresources
wouldberequiredtoimplementacombinedsetofcosteffective
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RESEARCHstrategies for the conditions scaled up for country-wide
coverage. Such information can contribute to renewed efforts
to scale up mental health services in low and middle income
countries.
5
Methods
Setting
In line with other papers in this series, results are provided for
two epidemiologically defined World Health Organization
sub-regions of the world: AfrE, which includes countries in the
WHOsub-SaharanAfricanregionwithhighchildandveryhigh
adultmortality(suchasKenyaandTanzania);andSearD,which
includes countries in the WHO South East Asia region with
high child and adult mortality (such as India and Nepal) (see
appendix A on bmj.com for a full list of countries within these
sub-regions).
Selection of disorders and interventions
Economicevaluationwascarriedoutforarangeofinterventions
relating to five prominent contributors to the global burden of
disease. Schizophrenia, bipolar affective disorder, and
depression each contribute at least 1% to the global burden of
disease,
6asdoalcoholusedisorders,butinthiscaseweextended
the scope to the broader and more burdensome entity of heavy
alcohol use (as a risk factor for neuropsychiatric and other
diseases, defined in terms of an average intake of >40 g of pure
alcohol daily for men and >20 g for women).
7 There is
substantial evidence for the effectiveness of interventions for
these conditions.
8 9 Analysis was also undertaken for epilepsy,
acommonandhighlytreatableneurologicaldisorderaccounting
for 0.5% of the global burden of disease.
10
Intervention analysis was not performed for other conditions
that, despite their potential inclusion within a comprehensive
mentalhealthprogramme,
5currentlyimposelessdiseaseburden
on populations or offer more limited scope for cost effective
prevention or treatment (such as anxiety disorders, dementia,
and developmental disorders).
Assessed interventions for the selected conditions cover both
individual and population based strategies, and were evaluated
at varying levels of feasible target population coverage (table
1⇓). All conditions and interventions are included in the WHO
mhGAP Intervention Guide
11 or, in the case of heavy alcohol
use,representcentralcomponentsoftheWHOGlobalStrategy
to Reduce the Harmful Use of Alcohol.
12
Estimation of intervention effectiveness
Intervention analysis for each of the conditions followed
standardWHO-CHOICEmethods,adoptinganepidemiological,
population based approach to assessing health outcomes (see
general appendix on bmj.com).
13 14 A first analytical step was
to generate a profile of the prevailing epidemiological situation
foreachconditionintermsofincidence,prevalence,remission,
and case fatality, as well as the average level of associated
disability (on a 0–1 scale, where 0 = no disability). These
parameters were derived from the Global Burden of Disease
6
or, in the case of heavy alcohol use, the Comparative
Quantification of Health Risks for 2004.
7 These estimates are
in turn based on representative country surveys that have been
undertaken in different sub-regions of the world (see appendix
A on bmj.com).
Observed epidemiological rates and disability weights were
enteredintoagenericstatetransitionmodel(PopMod)
14inorder
to establish the total amount of healthy life years experienced
over the 100 year lifetime of a defined population—in this case
wholeWHOsub-regions.Themodelwasthenre-runtoidentify
thedifferenceinhealthyyearslivedbythepopulationasaresult
of adding intervention effects (expressed as percentage change
tooneormoreofthemodelinputsforaperiodof10years,such
as an increase in the rate of remission or a reduction in average
disability level). In this way, we were able to compare the total
number of healthy years lived—equivalent to the number of
disability adjusted life years (DALYs) averted—with and
without intervention. In line with WHO burden of disease
estimation
6 7andstandardWHO-CHOICEmethods,
13 14DALYs
averted were discounted (at 3%) and weighted for age (see also
general appendix on bmj.com).
Sources of data for intervention efficacy and effectiveness
included meta-analyses, systematic reviews, and individual
clinical trials reported in the international literature, and are
describedindetailelsewhere.
15-19Table1⇓summarisesefficacy
estimates for the interventions (a more detailed review of data
sources for the efficacy of each intervention is presented in
appendix A on bmj.com). Target treatment coverage were set
at 80% for schizophrenia and epilepsy, 50% for affective
disorders,and30%forheavyalcoholuse.Thesewereconsidered
appropriate based on the severity of presenting symptoms and
established challenges of case identification and health seeking
behaviour for the latter conditions. Adherence rates for long
term therapies in the real world often fall to as low as 50%
(compared with at least 70% in most clinical trials),
20 so, with
theexceptionofinpatienttreatmentforseriousmentaldisorders
andbriefinterventionsforheavydrinkers,weadjustedreported
adherence from efficacy trials downwards by a factor of two
thirds in order to better approximate real world effectiveness.
Estimation of intervention costs
An“ingredients”approachtothecostingofhealthinterventions
was used,
13 14 requiring separate identification and valuation of
the quantity of all resource inputs needed (such as numbers of
staff) and the price or unit cost of those resource inputs (such
as salary of a nurse). For resource quantities at the patient level
(such as hospital inpatient days, outpatient visits, drugs,
laboratory tests), information sources include data from
economic evaluations and a multinational Delphi consensus
study.
21 Resource use profiles are described at appendix A on
bmj.com. Unit costs associated with these items of service use
have been estimated for the year 2005 for each WHO reporting
sub-region, based on econometric analysis of a multinational
dataset, using gross domestic product (GDP) per capita (plus
otherexplanatoryvariables)aspredictors(www.who.int/choice/
costs).Inaddition,programmecostswerecomputed,whichare
resources used at a level above that of the patient or providing
facility; these include central planning, policy formulation or
development,andadministrationfunctions,aswellasresources
devoted to training staff or enforcing laws.
Costs for the 10 year implementation period were discounted
at3%andexpressedininternationaldollars($Int),whichadjust
for differences in the relative price and purchasing power of
countriesandtherebyfacilitatecomparisonacrossregions(that
is,$Int1buysthesamequantityofhealthcareresourcesinKenya
orIndiaasitdoesintheUnitedStates;fortheAfricanandAsian
sub-regions used in this analysis, $Int1 is worth US$0.44 and
US$0.32 respectively).
Uncertainty analysis
In order to assess the inherent uncertainty around (point)
estimatesoftotalinterventioncostsandhealtheffects,anumber
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e609 doi: 10.1136/bmj.e609 (Published 2 March 2012) Page 2 of 10
RESEARCHof steps were carried out. Firstly, results were placed on a
logarithmic scale in order to ascertain order of magnitude
differences in cost effectiveness (for example, $Int10–100 v
$Int100–1000 per DALY averted). Secondly, results were
categorised according to a defined set of cost effectiveness
thresholds: WHO-CHOICE denotes as “cost effective” an
intervention that produces a healthy year of life for less than
three times the GDP per capita, and as “very cost effective” an
intervention that produces a healthy year of life for less than
GDPpercapita.Finally,forthesubsetofinterventionstrategies
that were dominant over others for the condition in
question—that is, those that are less costly or more effective,
or both, than other less efficient interventions—baseline data
(together with coefficients of variation amounting to 15–25%
aboveandbelowbaselinevalues)wereenteredintoananalytical
software package (MCLeague), which performs a probabilistic
uncertainty analysis using Monte Carlo simulation (1000 runs
were made using a truncated normal distribution).
14
Results
For a standardised population of one million people, table 2⇓
shows the costs, effects, and cost effectiveness of 44 individual
orcombinedinterventionsfortheselectedconditionsinthetwo
sub-regionsconsidered.Thesethreesetsofinformationarealso
showngraphicallyinfigures1⇓and2⇓,whichusealogarithmic
scale to display the wide variations in costs or effects (diagonal
lines show successive order of magnitude differences between
interventions, such as $Int100 v $Int1000 per DALY averted).
For sub-Saharan Africa (fig 1⇓), average cost effectiveness
ratios diverge by as much as two orders of magnitude (from a
littleover$Int100tomorethan$Int10000perDALYaverted),
meaning that the most efficient interventions for this cluster of
conditions (population based alcohol control policies) are 100
times more cost effective than the least efficient choices
(hospitalbasedtreatmentofschizophreniawithnewer,atypical
antipsychotic drugs). Toillustrate, current or increased taxation
on alcoholic drinks (coded as ALC-1, ALC-2, ALC-3 in table
2⇓)isestimatedtogenerateintherangeof1800–2000additional
healthy life years per million population each year at a cost of
$Int240 000 (that is, $Int0.24 per capita), whereas inpatient
based treatment of schizophrenia with newer antipsychotics
(without any psychosocial care and support, coded SCZ-6) is
estimated to generate 200 healthy life years and costs nearly
$Int5 million ($Int5 per capita). A far more cost effective
approach to the treatment of schizophrenia and of bipolar
affective disorder is to provide a community, outpatient based
serviceandofferolder(butnolesseffective)psychotropicdrugs
in conjunction with psychosocial treatments such as family
therapy.Withtheseinterventions,healthimprovementsbecome
appreciably higher, the cost per capita decreases dramatically
(to $Int1), and average cost effectiveness ratios come down to
$Int2500 for schizophrenia (SCZ-3) and $Int2750 for bipolar
disorder (BIP-2).
18 19 This range of cost effectiveness is still 10
times higher than that found for antiepileptic drug treatment in
primary care (EPI-1 and EPI-2), and three times greater than
that for episodic treatment of depression in primary care with
generic forms of newer antidepressants (DEP-2).
For South East Asia, results are similar to those for the African
region, which reflects not only similarities in underlying rates
of disease and outcome in the population but also input prices
on the cost side. The key difference in the Asian sub-region
relates to the relatively lower prevalence of heavy alcohol use,
with the result that population based alcohol interventions are
much less cost effective. Thus, implementation of alcohol
taxation policies generates only a fraction of the health gain
achieved in the African sub-region (70–90 DALYs averted per
million population each year). As a result, it is treatment of
depression that is expected to generate most health gain in the
population, and treatment of epilepsy that represents the most
cost effective use of resources in this setting.
Theincrementalorderingandselectionofthevariouscompeting
strategiesintermsoftheircosteffectivenessareshowninfigures
3⇓ and 4⇓, which show the order in which interventions would
be successively chosen across the five conditions (and at what
cumulativecost).ThusintheAfricansub-region,increasingthe
rate of tax on alcoholic drinks (by 50%) would be the first from
the 44 interventions considered since it has the lowest cost per
standardised unit of outcome (compared with the situation of
doing none of the interventions). The next most cost effective
choices would be other population based alcohol
interventions—enhancedtaxenforcementactivitiesandreduced
accesstoretailoutlets—followedbyepilepsytreatment(initially
at 50% coverage, and then expanding to 80%). Successively
less cost effective interventions for each of the conditions are
subsequently included. At the point that the last disease is
represented (schizophrenia), the cumulative cost per capita of
implementing a cost effective set of health maximising
interventions across this cluster of five conditions is estimated
at $Int5.70. A similar cumulative cost is estimated for SearD
($Int4.90), but in this case epilepsy then depression treatments
precedetheinclusionofpopulationbasedalcoholinterventions.
Finally,byenteringcostsandeffectivenessdataintoastochastic
uncertainty framework, it is possible to assess the impact of
plausible levels of variability around reported point estimates.
ThegraphicalresultspresentedinappendixBonbmj.comshow
that, even after allowing for this variability, the average cost
effectiveness ratios of interventions addressing depression,
epilepsy, and heavy alcohol use in the African sub-region
continue to fall completely or largely below the “very cost
effective” threshold of $Int2000 per healthy life year gained,
whilethemostefficientinterventionforschizophrenia(SCZ-3)
andbipolardisorder(BIP-1)predominantlyfallwithinthe“cost
effective” threshold of $Int6000 per healthy life year gained.
Similar results pertain to the South-East Asian sub-region,
exceptthatinterventionsaimedatcombatingheavyalcoholuse
largely fall outside the very cost effective threshold (but still
withinthecosteffectivethreshold).Thesamelogicwouldapply
to incremental cost effectiveness ratios.
Discussion
Key findings and implications
By employing a consistent methodological approach, this
sectoral analysis has been able to compare systematically the
costs and health outcomes of a broad set of interventions for
neuropsychiatric conditions that between them represent a
substantial source of global disease burden. One use of such an
exercise is to locate the relative position of these interventions
within a wider cost effectiveness framework in the healthcare
sector, as attempted in the final article of this series.
22 In the
current paper, the focus has not been to compare interventions
for neuropsychiatric conditions with those for other
non-communicable diseases but with each other—to determine
which, from an efficiency perspective, have the most claim on
resources for mental health. Such an exercise has not been
undertaken before for low resource settings. Earlier cost
effectiveness analyses focused on specific neuropsychiatric
conditions
15-19 and therefore did not allow for a broader
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conditions or intervention strategies.
The results show a wide range of the cost effectiveness of
possible actions that could be undertaken in the two selected
sub-regions in Africa and South East Asia, with the cost per
year of healthy life varying from many multiples to just a
fractionofaveragepercapitaincome.Useofapercapitaincome
threshold (around $Int2000 in these two sub-regions) provides
a convenient means for assessing the likely affordability of
current or future investments, and the evidence presented here
showsthatthereareplentyofcandidatesintheneuropsychiatric
interventions.Theseresultsarevaluableforhealthcareplanning
because the current practice in countries of these regions does
not match well with the economic evidence. A high proportion
of mental health budgets are currently being used in the
provision of the least cost effective interventions (such as long
term inpatient treatment of severe mental disorders),
2 and little
is invested in more cost effective strategies (including the
communitybasedprovisionofadjuvantpsychosocialtreatment
for severe mental disorders or measures to reduce access to or
marketing of alcohol).
From regional to national evaluation
In addition to political barriers,
23 the existence of cost
effectiveness information at the aggregate level of WHO
sub-regionsisnoguaranteethatfindingsandrecommendations
will actually change health policy at the national level (where
policies are determined and resources allocated). Accordingly,
thereisaneedtocontextualiseregionalestimatestothecountry
level, since many factors may influence the actual cost
effectiveness of a given intervention across settings; such a
process has now been undertaken in several WHO member
states, including Estonia, Mexico, Nigeria, Spain, Sri Lanka,
and Thailand.
19 24-26 Results from this process of country
contextualisation have shown a high degree of agreement with
regional rankings of cost effectiveness, but differences in the
absolute cost or specific effect of certain interventions (for
example, because of locally applicable drug price tariffs in
Nigeria or rates of heavy alcohol use in Thailand that were
higher than the regional average).
More broadly, there is a need to translate research into practice
and policies into action. WHO’s mental health Gap Action
Programme has been designed to do just that and is assisting
countries to scale up service provision in order to reduce the
substantial treatment gap that exists in so many low income
countries.
4 The financial cost of scaling up the provision of a
set of mental healthcare interventions in low income countries
has been estimated to be about US$2 ($Int3) per capita per
year.
27However,thisestimatedidnotincludeepilepsytreatment
or population based alcohol control measures, and used a lower
target coverage level for depression. For the target coverage
levels and fuller intervention set specified here, an updated
estimate would be US$3.25–3.80 ($Int4.90–5.70).
Study limits and limitations
Theprocessofcontextualisationdowntothelevelofindividual
countries represents an important test and validation of the
modelandresultsdevelopedbyWHO-CHOICE,butmodelling
exercises of this kind still have limitations, whatever the
geographical or resource setting. In particular, many of the
epidemiological and efficacy input values used were
international estimates: the empirical basis for estimates of the
use, cost, outcome, and impact of services for people with
neuropsychiatric conditions at the national level needs to be
improved, particularly for interventions with a substantial
behaviouralelement(suchastheeffectofpsychosocialtreatment
or the impact of restricting the marketing of and access to
alcohol).
The outcome of interest in cost effectiveness analyses of this
kind is the improvement of a population’s health, as opposed
to“non-health”attributesofsocialwelfare(includingimproved
productivity). Inclusion of the impact of interventions on
income,employment,orpoverty,forexample,wouldstrengthen
the economic rationale for scaling up services.
28 In the case of
demand reduction measures for alcohol—which has been
described as “no ordinary commodity”
9—consideration of the
various welfare consequences is complicated, since the health
and other benefits of their implementation (such as reduced
crime) would need to be viewed in light of higher prices or
greaterrestrictionsonconsumersandothereconomicoperators.
As such, the economic evidence presented here provides but
one of several inputs into decision making and resource
allocation.
Setting priorities for neuropsychiatric
conditions
For the broader task of priority setting, there is a need to go
beyond economic concerns only. Other criteria that need to be
considered include the relative severity and extent of spillover
effects among different diseases, the potential for reducing
catastrophic household spending on health, and protection of
human rights.
26 Priority setting necessarily implies a degree of
trade-off between different objectives of the mental health
system. Schizophrenia treatment, for example, risks being
overlooked on pure efficiency grounds in favour of more cost
effective strategies for more common mental disorders.
However, schizophrenia remains a priority condition for the
WHO and others
5 because of its severity, the risk of affected
people to be exposed to severe human rights violations, and its
often catastrophic effect on the welfare and income of family
members. Research into the economic and social consequences
of neuropsychiatric disorders on households is particularly
needed in resource constrained settings where health insurance
coverage is low, and amelioration of these adverse impacts
through appropriate intervention can only enhance the value or
worth of the strategies highlighted here.
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RESEARCHWhat is already known on this topic
Neuropsychiatric problems impose a substantial clinical, social, and economic burden on different regions of the world
Economic analysis for a subset of neuropsychiatric conditions has identified interventions that are expected to be cost effective for
combating neuropsychiatric problems in low and middle income countries
What this study adds
Simultaneous evaluation of the cost effectiveness of 44 individual or combined interventions for five key neuropsychiatric conditions
identified those that—from an efficiency perspective—have the most claim on resources for mental health in sub-Saharan Africa and
South East Asia
Alcohol control measures and drug treatment for epilepsy and depression were found to offer the best value for money
The cost per capita of a scaled up, combined package covering all assessed conditions is estimated to be US$3.25-3.80 ($Int4.90-5.70).
This package comprises the prevention or treatment of epilepsy (with older antiepileptic drugs); depression (with generic newer
antidepressant drugs and psychosocial treatment); bipolar disorder (with the mood-stabiliser lithium); schizophrenia (with neuroleptic
antipsychotic drugs and psychosocial treatment); and heavy alcohol use (via increased taxation and reduced accesses to alcohol and,
in the African sub-region, advertising bans and brief advice to heavy drinkers in primary care)
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Table 1| Assessed interventions for mental, neurological, and substance use conditions
Efficacy (% change)* Interventions Target coverage Setting(s) Condition
−15% to −30% (disability weight) Older antipsychotic drugs (such as haloperidol) versus newer
antipsychotics (such as risperidone), with or without adjuvant
psychosocial treatment (such as family psycho-education)
80% Hospital inpatient v
hospital outpatient
Schizophrenia
−50% to −53% (disability weight);
−65% (case fatality, for lithium only)
Mood stabiliser drug (lithium carbonate) versus
anticonvulsants (such as sodium valproate), with or without
adjuvant psychosocial treatment (such as family
psycho-education)
50% Hospital inpatient v
hospital outpatient
Bipolar disorder
25% to 40% (remission); −25%
(disability weight); −50%
(recurrence, for proactive care only)
Older (tricyclic) antidepressant drugs (such as amitriptyline)
versus newer antidepressants (generic SSRI such as
fluoxetine)
50% Primary health care Depression
Psychosocial treatment, alone or with drugs
Proactive maintenance treatment for recurrent cases (at
least two lifetime episodes of depression)
60% (remission); −43% (disability
weight)
Older, first line antiepileptic drugs (such as phenobarbitone,
phenytoin) versus newer antiepileptics (such as
carbamazepine, valproic acid)
80% Primary health care Epilepsy
14% to 18% (remission); −5.5%
(disability weight)
Brief physician advice 30% Primary health care Heavy alcohol use
−4.4% to −7.7% (incidence, for tax);
−2.5% to −3.0% (incidence, for
advertising bans or reduced
access); −3% to −4% (alcohol
related traffic fatality, for reduced
access only)
Excise tax (current plus 20-50% increase) 95% Population based
Advertising bans (comprehensive)
Reduced retail access (reduced opening hours)
SSRI = selective serotonin reuptake inhibitor.
*Improvement relative to the situation of no intervention; not adjusted for population-level effect modifiers (coverage, response, adherence).
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RESEARCHTable 2| Costs, effects, and cost effectiveness of interventions to combat mental, neurological, and substance use conditions in WHO
sub-Saharan African sub-region AfrE and South East Asian sub-region SearD
WHO Asian sub-region SearD WHO African sub-region AfrE
Intervention
Cost effectiveness ratio Annual
DALYs
saved per
million
population
Annual
cost per
capita
($Int)
Cost effectiveness ratio Annual
DALYs
saved per
million
population
Annual
cost per
capita
($Int) Incremental† Average* Incremental† Average*
Schizophrenia (all interventions at 80% coverage)
Dominated‡ 4657 174 0.81 Dominated‡ 5276 159 0.84 SCZ-1: Older antipsychotic drug
(community model)
Dominated‡ 15 046 210 3.16 Dominated‡ 14 749 193 2.84 SCZ-2: Newer antipsychotic drug
(community model)
2375 2375 363 0.86 2748 2748 332 0.91 SCZ-3: Older antipsychotic +
psychosocial treatment (community
model)
39 285 7663 423 3.24 36 504 7585 388 2.94 SCZ-4: Newer antipsychotic +
psychosocial treatment (community
model)
Dominated‡ 15 281 174 2.66 Dominated‡ 16 282 159 2.59 SCZ-5: Older antipsychotic (hospital
model)
Dominated‡ 23 833 210 5.01 Dominated‡ 23 852 193 4.59 SCZ-6: Newer antipsychotic (hospital
model)
Dominated‡ 6365 363 2.31 Dominated‡ 6816 332 2.26 SCZ-7: Older antipsychotic +
psychosocial treatment (hospital model)
Dominated‡ 11 085 423 4.69 Dominated‡ 11 072 388 4.29 SCZ-8: Newer antipsychotic +
psychosocial treatment (hospital model)
Bipolar disorder (all interventions at 50% coverage)
2001 2001 357 0.71 1800 1800 347 0.62 BIP-1: Older mood stabiliser (lithium)
(community model)
13 444 3048 392 1.20 9916 2551 382 0.98 BIP-2: Older mood stabiliser +
psychosocial care (community model)
Dominated‡ 3145 322 1.01 Dominated‡ 3448 248 0.86 BIP-3: Newer mood stabiliser (valproate)
(community model)
Dominated‡ 4210 354 1.49 Dominated‡ 4387 273 1.20 BIP-4: Newer mood stabiliser +
psychosocial care (community model)
Dominated‡ 5483 357 1.95 Dominated‡ 4678 347 1.62 BIP-5: Older mood stabiliser (hospital
model)
Dominated‡ 5864 392 2.30 Dominated‡ 4874 382 1.86 BIP-6: Older mood stabiliser +
psychosocial care (hospital model)
Dominated‡ 6476 322 2.08 Dominated‡ 6864 248 1.71 BIP-7: Newer mood stabiliser drug
(hospital model)
Dominated‡ 6913 354 2.45 Dominated‡ 7152 273 1.95 BIP-8: Newer mood stabiliser +
psychosocial care (hospital model)
Depression (all interventions at 50% coverage)
Dominated‡ 916 984 0.90 Dominated‡ 1029 610 0.63 DEP-1: Episodic treatment with older
antidepressants (TCAs)
756 756 1098 0.83 858 858 681 0.58 DEP-2: Episodic treatment with newer
antidepressants (SSRIs)
Dominated‡ 2957 1095 3.24 Dominated‡ 3225 679 2.19 DEP-3: Episodic psychosocial treatment
Dominated‡ 2416 1285 3.11 Dominated‡ 2641 797 2.10 DEP-4: Episodic psychosocial treatment
+ older antidepressants
Dominated‡ 2151 1412 3.04 Dominated‡ 2356 875 2.06 DEP-5: Episodic psychosocial treatment
+ newer antidepressants
Dominated‡ 1300 2343 3.05 Dominated‡ 1456 1452 2.12 DEP-6: Maintenance psychosocial
treatment + older antidepressants
1517 1178 2463 2.90 1704 1326 1526 2.02 DEP-7: Maintenance psychosocial
treatment + newer antidepressants
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RESEARCHTable 2 (continued)
WHO Asian sub-region SearD WHO African sub-region AfrE
Intervention
Cost effectiveness ratio Annual
DALYs
saved per
million
population
Annual
cost per
capita
($Int)
Cost effectiveness ratio Annual
DALYs
saved per
million
population
Annual
cost per
capita
($Int) Incremental† Average* Incremental† Average*
Epilepsy
286 286 519 0.15 265 265 1360 0.36 EPI-1: Older antiepileptic drug in primary
care at 50% coverage
300 292 830 0.24 325 288 2176 0.63 EPI-2: Older antiepileptic in primary care
at 80% coverage
Dominated‡ 518 519 0.27 Dominated‡ 465 1360 0.63 EPI-3: Newer antiepileptic in primary care
at 50% coverage
Dominated‡ 524 830 0.43 Dominated‡ 488 2176 1.06 EPI-4: Newer antiepileptic in primary care
at 80% coverage
Heavy alcohol use
Dominated‡ 1821 69 0.13 Dominated‡ 128 1794 0.23 ALC-1: Current taxation
Dominated‡ 1666 75 0.13 Dominated‡ 127 1812 0.23 ALC-2: Increased taxation (current +
20%)
1462 1462 86 0.13 117 117 1963 0.23 ALC-3: Increased taxation (current +
50%)
Dominated‡ 3281 75 0.24 Dominated‡ 183 2183 0.40 ALC-4: Reduced untaxed consumption
(current − 20%)
Dominated‡ 3454 83 0.29 Dominated‡ 164 2768 0.45 ALC-5: Reduced untaxed consumption
(current − 50%)
Dominated‡ 1677 56 0.09 Dominated‡ 212 799 0.17 ALC-6: Reduced access to retail outlets
(80% coverage)
Dominated‡ 3146 30 0.09 Dominated‡ 301 562 0.17 ALC-7: Comprehensive advertising ban
(80% coverage)
Dominated‡ 3837 29 0.11 Dominated‡ 822 461 0.38 ALC-8: Brief advice in primary care (30%
coverage)
Dominated‡ 2316 160 0.37 152 137 4494 0.61 ALC-9: Increased tax + scaled up tax
enforcement
1560 1500 139 0.21 Dominated‡ 140 2706 0.38 ALC-10: Increased tax + reduced access
Dominated‡ 1839 113 0.21 Dominated‡ 153 2475 0.38 ALC-11: Increased tax + advertising ban
Dominated‡ 2070 113 0.23 Dominated‡ 251 2375 0.60 ALC-12: Increased tax + brief advice
Dominated‡ 2244 140 0.32 Dominated‡ 255 2896 0.74 ALC-13: Increased tax + advertising ban
+ brief advice
3240 1788 166 0.30 Dominated‡ 167 3224 0.54 ALC-14: Increased tax + advertising ban
+ reduced access
3550 2207 218 0.48 224 151 5363 0.81 ALC-15: Increased tax + reduced access
+ tax enforcement
Dominated‡ 2120 191 0.40 Dominated‡ 250 3595 0.90 ALC-16: Increased tax + brief advice +
advertising ban + reduced access
4539 2593 261 0.68 783 220 6028 1.33 ALC-17: Increased tax + brief advice +
advertising ban + reduced access + tax
enforcement
DALYs=disability adjusted life years. $Int=international dollars. TCA=tricyclic antidepressants. SSRI=selective serotonin reuptake inhibitor.
*$Int per DALY averted relative to no intervention.
†$Int per DALY averted, within intervention cluster
‡Intervention is more costly or less effective than other more efficient interventions, and results are therefore not included here.
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RESEARCHFigures
Fig 1 Comparative cost per DALY averted for selected interventions to combat neuropsychiatric conditions in sub-Saharan
African sub-region AfrE. See table 2⇓ for explanation of intervention codes
Fig 2 Comparative cost per DALY averted for selected interventions to combat neuropsychiatric conditions in South East
Asian sub-region SearD. See table 2⇓ for explanation of intervention codes
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RESEARCHFig 3 Cost effectiveness of non-dominated interventions to combat neuropsychiatric conditions in sub-Saharan African
sub-region AfrE and cumulative cost per capita. See table 2⇓ for explanation of intervention codes
Fig 4 Cost effectiveness of non-dominated interventions to combat neuropsychiatric conditions in South East Asian sub-region
SearD and cumulative cost per capita. See table 2⇓ for explanation of intervention codes
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